INSV has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
INSV has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, InSite Vision's Enterprise Value is $45.34 Mil. InSite Vision's EBIT for the trailing twelve months (TTM) ended in Jun. 2015 was $-12.39 Mil. Therefore, InSite Vision's EV-to-EBIT for today is -3.66.
The historical rank and industry rank for InSite Vision's EV-to-EBIT or its related term are showing as below:
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. InSite Vision's Enterprise Value for the quarter that ended in Jun. 2015 was $34.57 Mil. InSite Vision's EBIT for the trailing twelve months (TTM) ended in Jun. 2015 was $-12.39 Mil. InSite Vision's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2015 was -35.84%.
The historical data trend for InSite Vision's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InSite Vision Annual Data | |||||||||||||||||||||
Trend | Dec05 | Dec06 | Dec07 | Dec08 | Dec09 | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | |||||||||||
EV-to-EBIT | Get a 7-Day Free Trial | 115.68 | 27.98 | 37.33 | 5.54 | -4.15 |
InSite Vision Quarterly Data | ||||||||||||||||||||
Sep10 | Dec10 | Mar11 | Jun11 | Sep11 | Dec11 | Mar12 | Jun12 | Sep12 | Dec12 | Mar13 | Jun13 | Sep13 | Dec13 | Mar14 | Jun14 | Sep14 | Dec14 | Mar15 | Jun15 | |
EV-to-EBIT | Get a 7-Day Free Trial | -7.64 | -5.69 | -4.15 | -6.89 | -2.79 |
For the Drug Manufacturers - Specialty & Generic subindustry, InSite Vision's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, InSite Vision's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where InSite Vision's EV-to-EBIT falls into.
InSite Vision's EV-to-EBIT for today is calculated as:
EV-to-EBIT | = | Enterprise Value (Today) | / | EBIT (TTM) |
= | 45.340 | / | -12.389 | |
= | -3.66 |
InSite Vision's current Enterprise Value is $45.34 Mil.
InSite Vision's EBIT for the trailing twelve months (TTM) ended in Jun. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was $-12.39 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InSite Vision (OTCPK:INSV) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.
InSite Vision's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2015 is calculated as:
Earnings Yield (Joel Greenblatt) % (Q: Jun. 2015 ) | = | EBIT | / | Enterprise Value (Q: Jun. 2015 ) |
= | -12.389 | / | 34.57069 | |
= | -35.84 % |
InSite Vision's Enterprise Value for the quarter that ended in Jun. 2015 was $34.57 Mil.
InSite Vision's EBIT for the trailing twelve months (TTM) ended in Jun. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was $-12.39 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of InSite Vision's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Louis Drapeau | officer: Vice President and CFO | C/O BIOMARIN PHARMACEUTICAL INC., 371 BEL MARIN KEYS BLVD., SUITE 210, NOVATO CA 94949 |
Brian Levy | director | |
Anthony J Yost | director | C/O INSITE VISION, INC., 965 ATLANTIC AVENUE, ALAMEDA CA 94501 |
Timothy Mcinerney | director | |
Craig A Tooman | director | |
Coliseum Capital Management, Llc | 10 percent owner | 105 ROWAYTON AVENUE, ROWAYTON CT 06853 |
Timothy P Lynch | director | 919 NW BOND STREET, SUITE 204, BEND OR 97703 |
Rick D Anderson | director | 3600 N CAPITAL OF TEXAS HWY, SUITE B180, AUSTIN TX 78746 |
Jon S Saxe | director | FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076 |
Francis Wen-hou Chen | director | 1821 JONES STREET, SAN FRANCISCO CA 94109 |
Pinto Tv Gp Co Llc | 10 percent owner | 3600 N CAPITAL OF TEXAS HWY, SUITE B180, AUSTIN TX 78746 |
Matthew S Crawford | 10 percent owner | 3600 N CAPITAL OF TEXAS HWY, SUITE B180, AUSTIN TX 78746 |
Pfizer Inc | 10 percent owner | 66 HUDSON BOULEVARD EAST, NEW YORK NY 10001-2192 |
No Headlines
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.